Location [1]
Synonyms [1]

TRA is altered in 0.20% of all cancers with breast invasive ductal carcinoma, endometrial endometrioid adenocarcinoma, colon adenocarcinoma, lung adenocarcinoma, and Burkitt lymphoma having the greatest prevalence of alterations [3].

TRA GENIE Cases - Top Diseases

The most common alterations in TRA are TRA-MYC Fusion (0.19%), TRA Fusion (0.05%), TRA-MTCP1 Fusion (0.02%), TRA-MIR548AI Fusion (0.01%), and TRA-SLC1A2 Fusion (0.01%) [3].

TRA GENIE Cases - Top Alterations

Significance of TRA in Diseases

Acute Lymphoblastic Leukemia +

Acute Myeloid Leukemia +

B-Cell Acute Lymphoblastic Leukemia +

Myelodysplastic Syndromes +


1. Hart R and Prlic A. Universal Transcript Archive Repository. Version uta_20180821. San Francisco CA: Github;2015. https://github.com/biocommons/uta

2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.

3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

4. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.